Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
6.25 x 4 6.31 x 6
Pre-market by (Cboe BZX)
6.63 -0.26 (-3.77%) 04/04/25 [NASDAQ]
6.25 x 4 6.31 x 6
Pre-market 6.30 -0.33 (-4.98%) 07:31 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.43
Day High
6.91
Open 6.83
Previous Close 6.89 6.89
Volume 4,813,400 4,813,400
Avg Vol 3,501,215 3,501,215
Stochastic %K 13.89% 13.89%
Weighted Alpha -77.35 -77.35
5-Day Change -1.44 (-17.84%) -1.44 (-17.84%)
52-Week Range 6.43 - 28.18 6.43 - 28.18
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 686,318
  • Shares Outstanding, K 103,517
  • Annual Sales, $ 57,880 K
  • Annual Income, $ -519,020 K
  • EBIT $ -534 M
  • EBITDA $ -524 M
  • 60-Month Beta 2.23
  • Price/Sales 12.32
  • Price/Cash Flow N/A
  • Price/Book 0.80

Options Overview Details

View History
  • Implied Volatility 129.42% ( +24.30%)
  • Historical Volatility 80.23%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 129.42% on 04/04/25
  • IV Low 54.50% on 08/21/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 961
  • Volume Avg (30-Day) 1,385
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 49,870
  • Open Int (30-Day) 47,540

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.26
  • Number of Estimates 10
  • High Estimate -0.89
  • Low Estimate -1.43
  • Prior Year -1.06
  • Growth Rate Est. (year over year) -18.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.43 +3.11%
on 04/04/25
Period Open: 9.10
10.68 -37.92%
on 03/07/25
-2.47 (-27.10%)
since 03/04/25
3-Month
6.43 +3.11%
on 04/04/25
Period Open: 12.13
13.34 -50.30%
on 01/07/25
-5.50 (-45.34%)
since 01/03/25
52-Week
6.43 +3.11%
on 04/04/25
Period Open: 24.97
28.18 -76.47%
on 07/17/24
-18.34 (-73.45%)
since 04/04/24

Most Recent Stories

More News
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 6.63 (-3.77%)
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA : 6.63 (-3.77%)
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

NTLA : 6.63 (-3.77%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

This aggressive growth investor is looking at the bright side when it's raining on Wall Street.

IRDM : 24.59 (-3.87%)
TSLA : 239.43 (-10.42%)
NTLA : 6.63 (-3.77%)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 6.63 (-3.77%)
Intellia Therapeutics Delivers a Q4 Beat

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue.

NTLA : 6.63 (-3.77%)
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

NTLA : 6.63 (-3.77%)
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next...

CRSP : 32.65 (-0.03%)
NTLA : 6.63 (-3.77%)
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

NTLA : 6.63 (-3.77%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 31.11 (-2.14%)
JNJ : 153.24 (-4.12%)
VRTX : 474.62 (-1.94%)
SNDX : 11.25 (-9.71%)
ABBV : 186.96 (-7.28%)
GERN : 1.3800 (-6.12%)
RHHBY : 37.6500 (-5.92%)
PFE : 22.97 (-5.43%)
NTLA : 6.63 (-3.77%)
BMY : 55.30 (-4.36%)
BIIB : 122.98 (-5.91%)

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 7.36
2nd Resistance Point 7.14
1st Resistance Point 6.88
Last Price 6.63
1st Support Level 6.40
2nd Support Level 6.18
3rd Support Level 5.92

See More

52-Week High 28.18
Fibonacci 61.8% 19.87
Fibonacci 50% 17.31
Fibonacci 38.2% 14.74
Last Price 6.63
52-Week Low 6.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades